Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (CF) (2010 - 2026)

Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 4.67% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (up 20.07% YoY) and the FY2025 annual result came in at $23.9 million, up 28.68% from the prior year.
• Depreciation & Amortization (CF) was $6.4 million for Q1 2026 at Arrowhead Pharmaceuticals, roughly flat from $6.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $6.4 million in Q4 2025 and bottomed at $2.6 million in Q1 2022.
• A 5-year average of $4.4 million and a median of $4.5 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) rose 2.89% — and 2024, when it soared 69.54%.
• Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) stood at $2.7 million in 2022, then soared by 58.53% to $4.3 million in 2023, then rose by 22.8% to $5.2 million in 2024, then climbed by 22.06% to $6.4 million in 2025, then declined by 0.34% to $6.4 million in 2026.
• Business Quant data shows ARWR's Depreciation & Amortization (CF) at $6.4 million in Q1 2026, $6.4 million in Q4 2025, and $6.4 million in Q3 2025.